216 results
Page 2 of 11
8-K
EX-99.1
huic5zxydyh3ly1e8q
28 Feb 22
Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation
4:26pm
8-K
EX-99.1
oww2 scwuyh8tsrc
6 Jan 22
Company expects preliminary estimated Q4 2021 revenues to be between $7.8-$8.0 million
8:40am
8-K
EX-10.1
vqyy8ew5frxutj3
28 Apr 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-1.1
psppa
4 Mar 21
Entry into a Material Definitive Agreement
4:26pm
424B5
fp85u
4 Mar 21
Prospectus supplement for primary offering
4:23pm
424B5
x9ojw4uolovi1ueb
2 Mar 21
Prospectus supplement for primary offering
4:26pm
8-K
EX-99.1
vez4ot2wlyxkrpshf91g
24 Feb 21
Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI ® Product Revenue
4:13pm
8-K
EX-99.1
3ou3lf48 8to
4 Aug 20
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
4:10pm
8-K
EX-99.1
l0pibst
11 May 20
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
4:24pm